Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.
Announcements
238
Total raised
£3.1B
disclosed amounts
This month
£7.8M
raised so far
The upsized funding round was led by existing backers including Ally Bridge Group and Lightrock.
"Versius is very well suited to our needs as a world-leading thoracic surgery department. We have successfully helped patients get the benefit of robotic assisted surgery and we look forward to developing our robotics programme working with CMR and other centres around the world as the adoption of Versius continues."
The investment will fund UK commercial rollout and US regulatory approval for the company's remote patient monitoring platform.
"Providing more care for people outside of hospital is not only beneficial for patients but is highly advantageous for healthcare providers,"
The Oxford-based medical technology company secured backing from Lauxera Capital Partners to expand its US footprint and advance research pipelines.
"Lauxera is proud and honoured to back the OrganOx team and its global commercial scale-up. This is the ninth investment made by Lauxera Growth I, a growth buy-out fund dedicated to investing in commercial-stage European and North American HealthTech businesses."
The financing was backed by Delin Ventures, AlbionVC, Playfair Capital and 11.2 Capital to support international growth and research programmes.
"We developed the uMed platform to help healthcare professionals more easily and efficiently run patient research and targeted care programmes at scale, improving outcomes for patients by mitigating care gaps and accelerating research. Our groundbreaking patient cohorts give researchers access to unique data and insights, accelerating development and access to new therapies, while dramatically reducing the cost of finding, engaging and collecting prospective data from patients."
Northstar Ventures and Par Equity co-led the investment round to support international expansion and US regulatory clearance.
"I’d like to thank Manus’ existing investors for supporting the Company’s commercialisation programme of our unique NeuroMotor PenTM , building on previous support we received in 2021. This year is set to be an exciting one, with partnerships already secured, and we truly believe our non-invasive and CE-marked product can have a huge impact on patients and tackle the unmet need for a quick, inexpensive device that can detect neurological conditions, particularly given the ageing global population."
